Ingeborg J.H. Vriens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingeborg J.H. Vriens has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adri C. Voogd
Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
2 shared publications - Nan Ding
Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands
2 shared publications - Renée Visserman2 shared publications
S.M.E. Geurts
2 shared publications- Christianne A. R. Lok
Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
1 shared publication - Esther M. Heuts
Department of General Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13
Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study
- 24 August 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13
Open AccessTreatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study
- Open Access
- 25 July 2026
- Published by Elsevier in The Breast
- Vol. 89
Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study
- 25 July 2026
- Published by Elsevier in The Breast
- Vol. 89
Open AccessReal-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study
- Open Access
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical practice and research priorities for anticancer drug treatment during pregnancy: an international survey
BackgroundPharmacological evidence to guide anticancer drug use during pregnancy remains limited, particularly for newer targeted and immunotherapeutic agents. Given the ethical and practical barriers to conducting clinical trials, coupled with the rapid introduction of new anticancer drugs, alternative strategies are needed to prioritize research and support model-informed dosing approaches.MethodsWe conducted an international electronic survey among clinicians experienced in the management of cancer during pregnancy. Respondents reported trimester-specific prescribing or consideration of anticancer and supportive drugs across multiple tumour types and rated the perceived need for further research. Prescribing behaviour was analysed at the physician–drug level using descriptive statistics, risk differences, and exploratory mixed-effects models. Survey findings were interpreted with input from a multidisciplinary focus group.ResultsTwenty-three clinicians completed the survey. Across tumour types, non-prescription predominated, particularly in the first trimester, with cautious and selective prescribing later in pregnancy. When considered, prescribing was largely confined to established anticancer drugs whereas targeted therapies and immunotherapies were generally avoided. Despite limited current use, a substantial perceived need for further research was identified. Immune checkpoint inhibitors and selected targeted agents were prioritized. Similar uncertainty was observed for commonly used supportive therapies, despite frequent prescribing.ConclusionsClinicians report caution in prescribing anticancer drugs during pregnancy alongside a clear need for further research, particularly for immunotherapies, targeted agents, and selected supportive drugs. These findings support a focused, model-informed research strategy to address key evidence gaps where clinical trials are not feasible.
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical practice and research priorities for anticancer drug treatment during pregnancy: an international survey
BackgroundPharmacological evidence to guide anticancer drug use during pregnancy remains limited, particularly for newer targeted and immunotherapeutic agents. Given the ethical and practical barriers to conducting clinical trials, coupled with the rapid introduction of new anticancer drugs, alternative strategies are needed to prioritize research and support model-informed dosing approaches.MethodsWe conducted an international electronic survey among clinicians experienced in the management of cancer during pregnancy. Respondents reported trimester-specific prescribing or consideration of anticancer and supportive drugs across multiple tumour types and rated the perceived need for further research. Prescribing behaviour was analysed at the physician–drug level using descriptive statistics, risk differences, and exploratory mixed-effects models. Survey findings were interpreted with input from a multidisciplinary focus group.ResultsTwenty-three clinicians completed the survey. Across tumour types, non-prescription predominated, particularly in the first trimester, with cautious and selective prescribing later in pregnancy. When considered, prescribing was largely confined to established anticancer drugs whereas targeted therapies and immunotherapies were generally avoided. Despite limited current use, a substantial perceived need for further research was identified. Immune checkpoint inhibitors and selected targeted agents were prioritized. Similar uncertainty was observed for commonly used supportive therapies, despite frequent prescribing.ConclusionsClinicians report caution in prescribing anticancer drugs during pregnancy alongside a clear need for further research, particularly for immunotherapies, targeted agents, and selected supportive drugs. These findings support a focused, model-informed research strategy to address key evidence gaps where clinical trials are not feasible.